Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study.
Kidney Res Clin Pract
December 2024
Department of Internal Medicine, Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Republic of Korea.
Background: Although the introduction of erythropoietin-stimulating agents (ESAs) has led to better clinical outcomes in patients undergoing hemodialysis (HD), fluctuations in hemoglobin (Hb) levels, known as Hb variability, are frequently observed. However, only a few studies have evaluated the association between Hb variability and nutritional status in patients undergoing HD.
Methods: In this prospective study conducted between March 1, 2020, and June 1, 2022, we included 109 patients aged over 20 years undergoing HD and receiving darbepoetin.
Roxadustat Efficacy and Safety in Patients Receiving Peritoneal Dialysis: Pooled Analysis of Four Phase 3 Studies.
J Clin Med
November 2024
Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo 142-8666, Japan.
Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved to treat anemia of chronic kidney disease (CKD). The efficacy and safety of roxadustat compared with parenteral erythropoiesis-stimulating agents (ESAs) were evaluated in patients with anemia of CKD receiving peritoneal dialysis (PD). This analysis pooled data from four phase 3, multicenter, randomized, open-label, active-comparator studies (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES).
View Article and Find Full Text PDFHyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study.
Adv Ther
November 2024
Fresenius Medical Care D GmbH, Bad Homburg, Germany.
Introduction: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in patients with anaemia of chronic kidney disease may lead to increased ESA doses to achieve target haemoglobin levels; however, elevated doses may be associated with increased mortality. Furthermore, patients with hyporesponsiveness to ESAs have poorer clinical outcomes than those who respond well to ESAs. Incidence and clinical characteristics of patients with ESA hyporesponsiveness were explored in a real-world setting.
View Article and Find Full Text PDFVadadustat Three Times Weekly in Patients With Anemia Due to Dialysis-Dependent CKD.
Am J Kidney Dis
November 2024
Emory University School of Medicine, Atlanta, GA.
Article Synopsis
- The study investigates the effectiveness and safety of using vadadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, as an alternative to the erythropoiesis-stimulating agent methoxy polyethylene glycol-epoetin beta (MPG-EPO) in treating anemia for patients with chronic kidney disease (CKD) who are on dialysis.
- This Phase 3b trial involved 456 adult participants, randomized into three groups receiving either vadadustat (at two different doses) or MPG-EPO, for up to 52 weeks, with a focus on changes in hemoglobin levels.
- Results showed that vadadustat was noninferior to MPG-EPO regarding hemoglobin change
Optimizing anemia management using artificial intelligence for patients undergoing hemodialysis.
Sci Rep
November 2024
Department of Internal Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, 156, Baengnyeong-ro, Chuncheon, 24289, Gangwon-do, Republic of Korea.
Patients with end-stage kidney disease (ESKD) frequently experience anemia, and maintaining hemoglobin (Hb) levels within a targeted range using erythropoiesis-stimulating agents (ESAs) is challenging. This study introduces a gated recurrent unit-attention-based module (GAM) for efficient anemia management among patients undergoing chronic dialysis and proposes a novel alert system for anticipating the need for red blood cell transfusions. Data on demographic characteristics, dialysis metrics, drug administration, laboratory tests, and transfusion history were retrospectively collected from patients undergoing hemodialysis at Kangwon National University Hospital between 2017 and 2022.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!